An inadequate dose of ribavirin is related to virological relapse by chronic hepatitis C patients treated with pegylated interferon alpha-2b and ribavirin

Journal of Infection and Chemotherapy

Volumn 18, Issue 5, 2012, Pages 689-697

  Ogawa, Eiichi ^a   Furusyo, Norihiro ^a   Kajiwara, Eiji ^b   Takahashi, Kazuhiro ^c   Nomura, Hideyuki ^d   Tanabe, Yuichi ^e   Satoh, Takeaki ^f   Maruyama, Toshihiro ^g   Nakamuta, Makoto ^h   Kotoh, Kazuhiro ⁱ   Azuma, Koichi ^j   Dohmen, Kazufumi ^k   Shimoda, Shinji ⁱ   Hayashi, Jun ^a  

^a KYUSHU UNIVERSITY HOSPITAL   (Japan)

^b STEEL MEMORIAL YAWATA HOSPITAL   (Japan)

^c HAMANOMACHI HOSPITAL   (Japan)

^d Shin Kokura Hospital   (Japan)

^e Fukuoka City Hospital   (Japan)

^f Kokura Medical Center   (Japan)

^g KITAKYUSHU MUNICIPAL MEDICAL CENTER   (Japan)

^h NATIONAL HOSPITAL ORGANIZATION   (Japan)

ⁱ KYUSHU UNIVERSITY   (Japan)

^j Kyushu Central Hospital   (Japan)

^k CHIHAYA HOSPITAL   (Japan)

more..

Author keywords

Hepatitis C virus; Pegylated interferon; Relapse; Ribavirin

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; CREATININE; GAMMA GLUTAMYLTRANSFERASE; HEMOGLOBIN; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BODY MASS; CLINICAL ASSESSMENT; CREATININE CLEARANCE; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; FEMALE; GENOTYPE; HEPATITIS C; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; RELAPSE; SENSITIVITY AND SPECIFICITY; SEX DIFFERENCE; THROMBOCYTE COUNT; TREATMENT DURATION; VIRAL CLEARANCE;

EID: 84871370458     PISSN: 1341321X     EISSN: 14377780     Source Type: Journal    
DOI: 10.1007/s10156-012-0396-5     Document Type: Article

References (38)

1. Sheff LB. Natural history of chronic hepatitis C. Hepatology. 2002;36:S35-46.
2. Hayashi J, Ohmiya M, Kishihara Y, Tani Y, Kinukawa N, Ikematsu H, et al. A statistical analysis of predictive factors of response to human lymphoblastoid interferon in patients with chronic hepatitis C. Am J Gastroenterol. 1994;89:2151-6.
3. Hayashi J, Kishihara Y, Ueno K, Yamaji K, Kawakami Y, Furusyo N, et al. Age-related response to interferon alfa treatment in women vs men with chronic hepatitis C virus infection. Arch Intern Med. 1998;158:177-81.
4. Furusyo N, Hayashi J, Ueno K, Sawayama Y, Kawakami Y, Kishihara Y, et al. Human lymphoblastoid interferon treatment for patients with hepatitis C virus-related cirrhosis. Clin Ther. 1997;19:1352-67.
5. Kashiwagi K, Furusyo N, Kubo N, Nakashima H, Nomura H, Kashiwagi S, et al. A prospective comparison of the effect of interferon-alpha and interferon-beta treatment in patients with chronic hepatitis C on the incidence of hepatocellular carcinoma development. J Infect Chemother. 2003;9:333-40.
6. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958-65.
7. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL Jr., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347: 975-82.
8. Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, et al. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. J Hepatol. 2007;46:403-10.
9. Furusyo N, Murata M, Ogawa E, Toyoda K, Ihara T, Ikezaki H, et al. Ribavirin concentration in the latter stages of 48-week pegylated interferon-alfa 2b plus ribavirin therapy for chronic hepatitis C is useful for predicting virological response. J Antimicrob Chemother. 2011;66:1127-39.
10. Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel-Fabiani F, Benzekri A, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIVinfected patients: a randomized controlled trial. JAMA. 2004;292: 2839-48.
11. Hadziyannis SJ, Sette H Jr., Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140: 346-55.
12. Poordad FF, Flamm SL. Virological relapse in chronic hepatitis C. Antivir Ther. 2009;14:303-13.
13. Shiffman ML, Salvatore J, Hubbard S, Price A, Sterling RK, Stravitz RT, et al. Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha. Hepatology. 2007;46:371-9.
14. Fried MW, Jensen DM, Rodriguez-Torres M, Nyberg LM, Di Bisceglie AM, Morgan TR, et al. Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: randomized study of higher doses of peginterferon alpha-2a and ribavirin. Hepatology. 2008;48:1033-43.
15. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412-9.
16. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 1996;24:289-93.
17. Jacobson IM, Brown RS Jr., Freilich B, Afdhal N, Kwo PY, Santoro J, et al. Peginterferon alfa-2b and weight-based or flatdose ribavirin in chronic hepatitis C patients: a randomized trial. Hepatology. 2007;46:971-81.
18. Fellay J, Thompson AJ, Ge D, Gumbs CE, Urban TJ, Shianna KV, et al. ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature. 2010;464:405-8.
19. Thompson AJ, Fellay J, Patel K, Tillmann HL, Naggie S, Ge D, et al. Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction. Gastroenterology. 2010;139:1181-9.
20. Furusyo N, Kubo N, Toyoda K, Takeoka H, Nabeshima S, Murata M, et al. Helper T cell cytokine response to ribavirin priming before combined treatment with interferon alpha and ribavirin for patients with chronic hepatitis C. Antiviral Res. 2005;67:46-54.
21. Asahina Y, Izumi N, Enomoto N, Uchihara M, Kurosaki M, Onuki Y, et al. Mutagenic effects of ribavirin and response to interferon/ribavirin combination therapy in chronic hepatitis C. J Hepatol. 2005;43:623-9.
22. Dixit NM, Perelson AS. The metabolism, pharmacokinetics and mechanisms of antiviral activity of ribavirin against hepatitis C virus. Cell Mol Life Sci. 2006;63:832-42.
23. Liu WL, Su WC, Cheng CW, Hwang LH, Wang CC, Chen HL, et al. Ribavirin up-regulates the activity of double-stranded RNAactivated protein kinase and enhances the action of interferonalpha against hepatitis C virus. J Infect Dis. 2007;196:425-34.
24. Shiffman ML, Ghany MG, Morgan TR, Wright EC, Everson GT, Lindsay KL, et al. Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology. 2007;132:103-12.
25. Berg T, von Wagner M, Nasser S, Sarrazin C, Heintges T, Gerlach T, et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology. 2006;130:1086-97.
26. Hiramatsu N, Oze T, Yakushijin T, Inoue Y, Igura T, Mochizuki K, et al. Ribavirin dose reduction raises relapse rate dose-dependently in genotype 1 patients with hepatitis C responding to pegylated interferon alpha-2b plus ribavirin. J Viral Hepat. 2009;16:586-94.
27. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med. 2011;364:2417-28.
28. Kumada H, Toyota J, Okanoue T, Chayama K, Tsubouchi H, Hayashi N. Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. J Hepatol. 2012;56:78-84.
29. Hézode C, Forestier N, Dusheiko G, Ferenci P, Pol S, Goeser T, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med. 2009;360:1839-50.
30. Furusyo N, Kajiwara E, Takahashi K, Nomura H, Tanabe Y, Masumoto A, et al. Association between the treatment length and cumulative dose of pegylated interferon alpha-2b plus ribavirin and their effectiveness as a combination treatment for Japanese chronic hepatitis C patients: project of the Kyushu University Liver Disease Study Group. J Gastroenterol Hepatol. 2008;23: 1094-104.
31. Muir AJ, Bornstein JD, Atlantic Coast Hepatitis Treatment Group. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med. 2004;350:2265-71.
32. Ogawa E, Furusyo N, Toyoda K, Takeoka H, Maeda S, Hayashi J. The longitudinal quantitative assessment by transient elastography of chronic hepatitis C patients treated with pegylated interferon alpha-2b and ribavirin. Antiviral Res. 2009;83:127-34.
33. Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, et al. Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b. J Med Virol. 2007;79:1686-95.
34. Ginaldi L, Loreto MF, Corsi MP, Modesti M, De Martinis M. Immunosenescence and infectious diseases. Microbes Infect. 2001;3:851-7.
35. Gao B, Hong F, Radaeva S. Host factors and failure of interferonalpha treatment in hepatitis C virus. Hepatology. 2004;39: 880-90.
36. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009;41:1105-9.
37. Balagopal A, Thomas DL, Thio CL. IL28B and the control of hepatitis C virus infection. Gastroenterology. 2010;139:1865-76.
38. Thompson AJ, Muir AJ, Sulkowski MS, Ge D, Fellay J, Shianna KV, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology. 2010;139:120-9.